SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

Yannis Metaxas, Roger von Moos, E.I. Eboulet et al.|Annals of Oncology|2019

Cited by 2